Age-Related Macular Degeneration (ARMD) Terminated Phase 3 Trials for Pegpleranib (DB06325)

Also known as: Age-related macular degeneration / Macular Degeneration / Senile macular degeneration / Macular degeneration senile / Macular degeneration (senile) of retina, unspecified

IndicationStatusPhase
DBCOND0034150 (Age-Related Macular Degeneration (ARMD))Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01944839A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTreatment
NCT01940900A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTreatment
NCT01940887A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® MonotherapyTreatment